WS Investor
29 Apr 2026, 17:00
AbbVie Beats Q1 Expectations, Raises Full-Year Outlook as Skyrizi and Rinvoq Power Growth
AbbVie (NYSE: ABBV) reported strong first-quarter 2026 results, exceeding analyst expectations and prompting the pharmaceutical giant to raise its full-year earnings guidance.
The company posted net revenues of $15.0 billion for the quarter, representing a 12.4% increase on a reported basis. Adjusted diluted EPS came in at $2.65, a 7.7% year-over-year improvement and ahead of the consensus estimate of $2.59. On a GAAP basis, diluted EPS fell to $0.39 — a decline of 45.8% — largely due to a $0.41-per-share charge tied to acquired in-process research and development (IPR&D) and milestone expenses.
Immunology Leads the Way
AbbVie's immunology franchise remained the engine of growth, generating $7.29 billion in global net revenues, up 16.4% year-over-year. Skyrizi pulled in $4.48 billion and Rinvoq contributed $2.12 billion — both continuing their rapid ascent as replacements for Humira, which brought in a comparatively modest $688 million as biosimilar competition continues to erode its dominance.
Neuroscience Surges
The neuroscience portfolio was another standout, with revenues climbing 26.0% to $2.88 billion. Botox Therapeutic crossed the $1 billion mark at $1.009 billion, while Vraylar contributed $905 million and migraine treatments Ubrelvy and Qulipta combined for $635 million.
Oncology Under Pressure
The oncology segment was a relative weak spot, slipping 0.2% to $1.63 billion. Imbruvica, facing intensifying competition and government drug-pricing negotiations, brought in $556 million, while Venclexta led the portfolio at $770 million.
Guidance Raised
On the strength of the quarter, AbbVie lifted its 2026 adjusted diluted EPS guidance to a range of $14.08–$14.28, up from the prior range of $13.96–$14.16. CEO Robert A. Michael called it "an excellent start to 2026," citing strong performance from key growth drivers and a pipeline advancing across all stages of development.
Stock Snapshot
ABBV shares have traded around $200 today, hovering near $204–$205 following the earnings release. The stock is down roughly 13% year-to-date, though today's strong results may offer a near-term catalyst. Its 52-week high stands at $244.81, about 20% above current levels. (Robinhood)
AbbVie (NYSE: ABBV) reported strong first-quarter 2026 results, exceeding analyst expectations and prompting the pharmaceutical giant to raise its full-year earnings guidance.
The company posted net revenues of $15.0 billion for the quarter, representing a 12.4% increase on a reported basis. Adjusted diluted EPS came in at $2.65, a 7.7% year-over-year improvement and ahead of the consensus estimate of $2.59. On a GAAP basis, diluted EPS fell to $0.39 — a decline of 45.8% — largely due to a $0.41-per-share charge tied to acquired in-process research and development (IPR&D) and milestone expenses.
Immunology Leads the Way
AbbVie's immunology franchise remained the engine of growth, generating $7.29 billion in global net revenues, up 16.4% year-over-year. Skyrizi pulled in $4.48 billion and Rinvoq contributed $2.12 billion — both continuing their rapid ascent as replacements for Humira, which brought in a comparatively modest $688 million as biosimilar competition continues to erode its dominance.
Neuroscience Surges
The neuroscience portfolio was another standout, with revenues climbing 26.0% to $2.88 billion. Botox Therapeutic crossed the $1 billion mark at $1.009 billion, while Vraylar contributed $905 million and migraine treatments Ubrelvy and Qulipta combined for $635 million.
Oncology Under Pressure
The oncology segment was a relative weak spot, slipping 0.2% to $1.63 billion. Imbruvica, facing intensifying competition and government drug-pricing negotiations, brought in $556 million, while Venclexta led the portfolio at $770 million.
Guidance Raised
On the strength of the quarter, AbbVie lifted its 2026 adjusted diluted EPS guidance to a range of $14.08–$14.28, up from the prior range of $13.96–$14.16. CEO Robert A. Michael called it "an excellent start to 2026," citing strong performance from key growth drivers and a pipeline advancing across all stages of development.
Stock Snapshot
ABBV shares have traded around $200 today, hovering near $204–$205 following the earnings release. The stock is down roughly 13% year-to-date, though today's strong results may offer a near-term catalyst. Its 52-week high stands at $244.81, about 20% above current levels. (Robinhood)